Your English writing platform
Discover LudwigSuggestions(1)
Similar(60)
The most prominent dose-limiting side effects on regimens with twice-daily (b.i.d).
HDAC inhibitors (HDACi) are currently tested in the treatment of a wide range of malignancies and transient but severe thrombocytopenia is their prominent, dose-limiting side effect.
Paclitaxel causes neuropathy as a prominent dose-limiting side effect [ 3] and induces microtubule aggregation in the peripheral nervous system [ 4] and interruptions in anterograde axonal transport [ 5], suggesting that microtubule dysfunction may be important in the development of neuropathy.
IRs were dose limiting above 250mg.
Dose limiting toxicity was not experienced.
One dose limiting toxicity occurred at dose level 2 (prolonged thrombocytopenia), and the recommended phase 2 dose was established at 30mg twice daily.
Doses for capecitabine, oxaliplatin and everolimus were modified per dose limiting toxicity (DLT).
Hematological toxicity was dose limiting and correlated with the administered 131I dose.
Thrombocytopenia was dose limiting, but highly variable among patients at a given dose level; other toxicity was mild and uncommon.
Myelotoxicity was dose limiting.
DLT, dose limiting toxicity.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com